A Phase I/Biomarker Study of Bevacizumab in Combination With CNTO 95 in Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2015
At a glance
- Drugs Bevacizumab (Primary) ; Intetumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 May 2014 Planned End Date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 05 Apr 2013 Planned end date changed from 1 Mar 2011 to 1 Mar 2014 as reported by ClinicalTrials.gov.